Received Sep 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | 37R35 | — |
Boostrix accidental dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate schedule of vaccine administered in a 62-year-old male patient who received DTPa (Reduced antigen) (Boostrix) (batch number 37R35, expiry date 21-OCT-2027) for prophylaxis. Previously administered products included Boostrix (received 1st dose on 30-APR-2013) and Boostrix (received 2nd dose on 17-AUG-2023). On 21-AUG-2025, the patient received the 3rd dose of Boostrix. On 21-AUG-2025, an unknown time after receiving Boostrix, the patient experienced inappropriate schedule of vaccine administered (Verbatim: Boostrix accidental dose). The outcome of the inappropriate schedule of vaccine administered was not applicable. It was unknown if the reporter considered the inappropriate schedule of vaccine administered to be related to Boostrix. It was unknown if the company considered the inappropriate schedule of vaccine administered to be related to Boostrix. Additional Information: GSK Receipt Date: 21-AUG-2025 The medical assistant called to report a dose of Boostrix was given on 21st August 2025 accidentally to a patient. Patient had previously received Boostrix on 17th August 2023 and on 30th April 2013. On the day of reporting the patient also received a pneumonia vaccine. The healthcare professional confirmed accidental dose would be the third dose of Tdap in total for the patient which led to inappropriate schedule of vaccine administration.